This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A 2nd Look: Discussing the FDA Approval of Medtronic's OmniaSecure Defibrillation Lead for Conduction System Pacing

Ticker(s): MDT, BSX, ABT

Who's the expert?

Institution: University of Pennsylvania (Hospital of the University of Pennsylvania)

  • Interventional cardiologist and cardiac electrophysiologist specializing in cardiac rhythm disorders, including atrial fibrillation, ventricular tachycardia, and sudden cardiac death, with expertise in device implantation and lead management.
  • Treats hundreds of patients annually requiring pacing systems, defibrillators, and complex electrophysiology procedures, including catheter ablation and lead extraction.
  • Primary research and clinical focus is on cardiac implantable electronic devices, lead management and extraction, and improving outcomes in arrhythmia management and sudden cardiac death prevention.

Interview Questions
Q1.

How are you currently approaching device selection and lead strategy in patients requiring pacing and/or defibrillation, and what factors influence your use of conduction system pacing?

Added By: sara_admin
Q2.

How do you anticipate this technology impacting procedural approaches, including implantation techniques, workflow, and operator training?

Added By: sara_admin
Q3.

In which patient populations do you see the greatest potential benefit from combining defibrillation capability with conduction system pacing?

Added By: sara_admin
Q4.

What is your level of excitement for the OmniaSecure on a scale of 1-10?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.